Tag: volume

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Platinum and Palladium Trust (NYSE: SPPP) (TSX: SPPP / SPPP.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical platinum and palladium bullion, today announced that it has updated its at-the-market equity program to issue up to U.S.$100 million of units of the Trust (“Units”) in the United States and Canada.

Logent Finland Bidco Oy, an indirect subsidiary of SSCP Lager BidCo AB (publ) (“Logent” or the “Company”) has entered into an agreement with the shareholders of the Finnish entity HUB logistics Finland Oy (“HUB logistics” or the “Target”) to acquire all the shares in the Target (the “Acquisition”). The closing of the Acquisition is expected to take effect on 23 June 2025 and is subject to customary conditions precedents.

RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) -- In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully performed an endoscopic sleeve gastroplasty (ESG) on a patient who had previously undergone a kidney transplant, a case that requires meticulous management of immunosuppressive medications and the prevention of any complications that could jeopardize the transplanted organ. This procedure marks a significant advancement in providing safe treatment solutions for transplant recipients, to improve their graft survival and quality of life.

Suominen Corporation June 12, 2025 at 3:15 p.m. (EEST)

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

SINGAPORE, June 12, 2025 (GLOBE NEWSWIRE) -- HTX, a leading global cryptocurrency exchange, officially launched its highly anticipated TRX options products on June 11, further enhancing its robust derivatives offerings. This development provides users with greater trading flexibility and additional tools to manage risk and pursue profit in a dynamic market environment. The introduction of TRX options marks a key step in HTX's strategic roadmap toward a comprehensive and resilient derivatives ecosystem. Through ongoing product innovation, HTX continues to reinforce its competitive edge in the global derivatives market.

Driven by Stable Legacy Sales and Ongoing Cost Savings Initiatives